Surgery with or without preoperative paclitaxel and carboplatin in early-stage non - small-cell lung cancer: Southwest oncology group trial S9900, an intergroup, randomized, phase III trial

Katherine M W Pisters, Eric Vallières, John J. Crowley, Wilbur A. Franklin, Paul A. Bunn, Robert J. Ginsberg, Joe B. Putnam, Kari Chansky, David Gandara

Research output: Contribution to journalArticle

139 Scopus citations

Abstract

Purpose: Patients with early-stage non - small-cell lung cancer (NSCLC) have a poor prognosis even after complete resection. Earlier studies of preoperative (induction) chemotherapy in resectable NSCLC demonstrated feasibility and encouraging survival data. This randomized phase III trial compared overall survival (OS) for preoperative paclitaxel and carboplatin followed by surgery with surgery alone in patients with early-stage NSCLC. Patients and Methods: Patients with clinical stage IB-IIIA NSCLC (excluding superior sulcus tumors and N2 disease) were eligible. Patients were randomly assigned to surgery alone or to three cycles of paclitaxel (225 mg/m 2) and carboplatin (area under curve, 6) followed by surgical resection. The primary end point was OS; secondary end points were progression-free survival (PFS), chemotherapy response, and toxicity. Results: The trial closed early with 354 patients after reports of a survival benefit for postoperative chemotherapy in other studies. The median OS was 41 months in the surgery-only arm and 62 months in the preoperative chemotherapy arm (hazard ratio, 0.79; 95% CI, 0.60 to 1.06; P = .11.) The median PFS was 20 months for surgery alone and 33 months for preoperative chemotherapy (hazard ratio, 0.80; 95% CI, 0.61 to 1.04; P = .10.) Major response to chemotherapy was seen in 41% of patients; no unexpected toxicity was observed. Conclusion This trial closed prematurely after compelling evidence supporting postoperative chemotherapy emerged. Although OS and PFS were higher with preoperative chemotherapy, the differences did not reach statistical significance. At present, stronger evidence exists for postoperative chemotherapy in early-stage NSCLC.

Original languageEnglish (US)
Pages (from-to)1843-1849
Number of pages7
JournalJournal of Clinical Oncology
Volume28
Issue number11
DOIs
StatePublished - Apr 10 2010

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Surgery with or without preoperative paclitaxel and carboplatin in early-stage non - small-cell lung cancer: Southwest oncology group trial S9900, an intergroup, randomized, phase III trial'. Together they form a unique fingerprint.

  • Cite this